Saira Ramasastry - 26 May 2021 Form 3 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
26 May 2021
Net transactions value
$0
Form type
3
Filing time
26 May 2021, 21:06:11 UTC
Previous filing
25 May 2021
Next filing
25 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DAWN Common Stock 50,485 26 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DAWN Stock Option (right to buy Common Stock) 26 May 2021 Common Stock 40,000 $16.00 Direct F2
holding DAWN Stock Option (right to buy Common Stock) 26 May 2021 Common Stock 47,581 $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F2 The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 The option vests as to 1/48th of the total shares on each monthly anniversary, beginning on May 6, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.